Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in several upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in several upcoming investor conferences. The Guggenheim Healthcare Talks: 4th Annual Neuro/Immunology Conference will take place on November 14, 2022, at 2:45 PM ET. The Jefferies London Healthcare Conference is scheduled for November 16, 2022, at 9:10 AM BST / 4:10 AM ET. Lastly, the 5th Annual Evercore ISI HealthCONx Conference is set for December 1, 2022, at 1:25 PM ET. Management will hold one-on-one meetings during these events. Webcasts and recordings will be available on Phathom’s website for 90 days post-event.
Details
News Market Reaction – PHAT
The recorded move for PHAT in the trading session of this news was -2.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of its management team will participate in upcoming investor conferences:
Guggenheim Healthcare Talks: 4th Annual Neuro/Immunology Conference
- Presentation Date: November 14, 2022
- Presentation Time: 2:45 PM ET
Jefferies London Healthcare Conference
- Presentation Date: November 16, 2022
- Presentation Time: 9:10 am BST / 4:10 am ET
5th Annual Evercore ISI HealthCONx Conference
- Presentation Date: December 1, 2022
- Presentation Time: 1:25 PM ET
Company management will also participate in one-on-one meetings throughout the duration of each conference.
To access the live webcast and archived recordings of the presentations, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recordings will be available for 90 days following the event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Vonoprazan-based regimens are approved in the U.S. as part of a co-packaged product in combination with antibiotics for the treatment of H. pylori infection in adults, marketed as VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin). Phathom has a New Drug Application under review by the FDA for vonoprazan in erosive esophagitis (EE) and is studying the use of vonoprazan for the treatment of non-erosive reflux disease (NERD). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.
MEDIA AND INVESTOR CONTACT:
Nick Benedetto
1-877-742-8466
media@phathompharma.com
ir@phathompharma.com
© 2022 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks or trademarks of Phathom Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.